

Filippo Montemurro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9207220/publications.pdf>

Version: 2024-02-01

150
papers

5,277
citations

87723

38
h-index

102304

66
g-index

154
all docs

154
docs citations

154
times ranked

7463
citing authors

#	ARTICLE	IF	CITATIONS
1	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	0.6	1
2	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
3	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 2468.	1.7	5
4	The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. <i>Cells</i> , 2022, 11, 1944.	1.8	0
5	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
6	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. <i>Nature Communications</i> , 2021, 12, 2498.	5.8	20
7	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2711-2720.	2.0	11
8	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	2.3	6
9	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	0.8	0
10	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
11	Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?. <i>Lancet Oncology</i> , The, 2020, 21, 21-24.	5.1	8
12	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	2.0	5
13	Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. <i>Annals of Oncology</i> , 2020, 31, 1350-1358.	0.6	206
14	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. <i>ESMO Open</i> , 2020, 5, e000937.	2.0	10
15	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. <i>ESMO Open</i> , 2020, 5, e000876.	2.0	12
16	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	5.1	441
17	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	1.3	6
18	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1203.	3.4	19

#	ARTICLE	IF	CITATIONS
19	Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study. <i>Cancers</i> , 2020, 12, 327.	1.7	2
20	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1071-1082.	0.9	62
21	Cancer of Unknown Primary (<scp>CUP</scp>): genetic evidence for a novel nosological entity? A case report. <i>EMBO Molecular Medicine</i> , 2020, 12, e11756.	3.3	10
22	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLEET study. <i>Oncotarget</i> , 2020, 11, 2172-2181.	0.8	5
23	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0,784314,ggBT /Over 1137.	1.7	22
24	Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. <i>European Journal of Cancer</i> , 2019, 109, 92-102.	1.3	73
25	A new player in the treatment of HER2-positive tumours. <i>Lancet Oncology, The</i> , 2019, 20, 748-750.	5.1	3
26	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019, 25, 444-449.	0.4	6
27	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
28	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019, 11, 1661.	1.7	48
29	What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 5-9.	0.9	7
30	Metastatic Cancer of Unknown Primary or Primary Metastatic Cancer?. <i>Frontiers in Oncology</i> , 2019, 9, 1546.	1.3	35
31	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 474-485.	5.1	59
32	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	0.9	4
33	Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. <i>Breast</i> , 2018, 38, 160-164.	0.9	16
34	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 37, 142-147.	0.9	29
35	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	1.6	53
36	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. <i>European Journal of Cancer</i> , 2018, 105, 61-70.	1.3	8

#	ARTICLE	IF	CITATIONS
37	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	2.1	20
38	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 41, 137-143.	0.9	41
39	Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Medicine</i> , 2018, 7, 4339-4344.	1.3	29
40	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLETT Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017, 22, 648-654.	1.9	10
41	Trastuzumab emtansine in HER2-positive metastatic breast cancer. <i>Lancet Oncology</i> , The, 2017, 18, 696-697.	5.1	5
42	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	1.1	30
43	Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 85-95.	1.1	18
44	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	1.3	39
45	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 β Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	7.7	69
46	A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features. <i>British Journal of Radiology</i> , 2017, 90, 20170269.	1.0	25
47	Treating breast cancer with cell-based approaches: an overview. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1255-1264.	1.4	4
48	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. <i>ESMO Open</i> , 2017, 2, e000253.	2.0	56
49	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017, 13, 2791-2797.	1.1	23
50	Efficacy and safety of T-DM1 in the "common-practice" of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017, 8, 64481-64489.	0.8	22
51	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	1.1	2
52	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLETT). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64
53	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2016, 1, e000109.	2.0	2
54	Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1039-1041.	0.9	0

#	ARTICLE	IF	CITATIONS
55	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2179-2189.	0.9	9
56	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 1-7.	3.4	8
57	Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life. <i>SpringerPlus</i> , 2016, 5, 59.	1.2	33
58	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
59	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 211-218.	1.1	11
60	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
61	Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 393-403.	1.9	3
62	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 445.	3.4	55
63	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. <i>Oncotarget</i> , 2016, 7, 4442-4453.	0.8	8
64	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
65	Breast cancer in BRCA mutation carriers: medical treatment. <i>Minerva Ginecologica</i> , 2016, 68, 557-65.	0.8	2
66	Clinical utility of exemestane in the treatment of breast cancer. <i>International Journal of Women's Health</i> , 2015, 7, 551.	1.1	13
67	Linifanib: current status and future potential in cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 677-687.	1.1	21
68	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431.	1.9	29
69	HER2-positive metastatic breast cancer: A changing scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 78-87.	2.0	29
70	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	6.3	164
71	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 241-245.	0.4	12
72	Complications of hyperglycaemia with PI3K/“AKT”/mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. <i>British Journal of Cancer</i> , 2015, 113, 1541-1547.	2.9	30

#	ARTICLE	IF	CITATIONS
73	Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer. <i>Cell Reports</i> , 2015, 11, 564-576.	2.9	52
74	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	1.9	26
75	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. <i>Oncotarget</i> , 2015, 6, 2315-2330.	0.8	43
76	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 511-523.	1.1	34
77	2013 San Antonio Breast Cancer Symposium. Expert Opinion on Pharmacotherapy, 2014, 15, 1191-1195.	0.9	0
78	HER2 expression and efficacy of T-DM1. <i>Breast Cancer Research</i> , 2014, 16, 478.	2.2	1
79	Vertebral Augmentation with Nitinol Endoprosthesis: Clinical Experience in 40 Patients with 1-Year Follow-up. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 193-202.	0.9	11
80	Biomarkers of drugs targeting HER family signalling in cancer. <i>Journal of Pathology</i> , 2014, 232, 219-229.	2.1	49
81	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37
82	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014, 23, 44-49.	0.9	25
83	Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. <i>Breast</i> , 2014, 23, 690-691.	0.9	6
84	Metastatic breast cancer subtypes and central nervous system metastases. <i>Breast</i> , 2014, 23, 623-628.	0.9	95
85	Duration of trastuzumab for HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 678-679.	5.1	3
86	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. <i>Journal of Pathology</i> , 2013, 229, 390-399.	2.1	16
87	Upfront adjuvant aromatase inhibitors in women with lobular breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3376-3377.	1.3	1
88	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 1740-1748.	0.6	74
89	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. <i>Annals of Oncology</i> , 2013, 24, 2715-2724.	0.6	106
90	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1436-1441.	0.6	31

#	ARTICLE	IF	CITATIONS
91	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	1.9	79
92	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156.	0.9	6
93	Imaging as a potential tool for subtyping breast cancer. <i>Imaging in Medicine</i> , 2012, 4, 577-579.	0.0	0
94	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	0.7	20
95	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. <i>European Journal of Cancer</i> , 2012, 48, 2311-2318.	1.3	55
96	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. <i>Oncology Letters</i> , 2012, 3, 819-824.	0.8	12
97	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 131.	1.0	12
98	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012, 22, 1519-1528.	2.3	206
99	Hormone receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012, 118, 17-26.	2.0	58
100	Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 139-145.	0.9	47
101	Neoadjuvant Therapy in Breast Cancer. , 2012, , 95-108.		0
102	Percutaneous Vertebroplasty in Osteoporotic Patients: An Institutional Experience of 1,634 Patients with Long-Term Follow-Up. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1714-1720.	0.2	30
103	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011, 25, 1545-8.	1.2	4
104	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177.	0.2	0
105	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 29-40.	1.1	47
106	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. <i>BMC Cancer</i> , 2011, 11, 31.	1.1	86
107	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 549-565.	0.9	9
108	Variation of Breast Vascular Maps on Dynamic Contrast-Enhanced MRI After Primary Chemotherapy of Locally Advanced Breast Cancer. <i>American Journal of Roentgenology</i> , 2011, 196, 1214-1218.	1.0	19

#	ARTICLE	IF	CITATIONS
109	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. <i>Oncologist</i> , 2011, 16, 534-536.	1.9	1
110	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. <i>BMC Cancer</i> , 2010, 10, 28.	1.1	13
111	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 93.	1.0	8
112	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672.	1.9	8
113	Anthracycline-based adjuvant chemotherapy in breast cancer. <i>Lancet, The</i> , 2010, 375, 1871.	6.3	0
114	Trastuzumab Beyond Disease Progression: Case Closed?. <i>Journal of Clinical Oncology</i> , 2009, 27, e121-e122.	0.8	5
115	Reply to A. Snchez-Muoz et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e257-e258.	0.8	0
116	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. <i>Endocrine-Related Cancer</i> , 2009, 16, 1091-1102.	1.6	29
117	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2566-2567.	0.8	10
118	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 209.	1.1	8
119	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442.	1.1	25
120	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2052-2053.	0.8	13
121	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. <i>Acta Oncolgica</i> , 2007, 46, 664-668.	0.8	46
122	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 398-399.	4.3	2
123	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 257-268.	1.4	96
124	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. <i>Annals of Oncology</i> , 2007, 18, 1963-1968.	0.6	12
125	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1179-1188.	0.9	0
126	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. <i>Annals of Oncology</i> , 2007, 18, 977-984.	0.6	498

#	ARTICLE	IF	CITATIONS
127	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007, 17, 1490-1497.	2.3	56
128	Trastuzumab Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2186-2186.	13.9	11
129	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. <i>Acta OncolÃ³gica</i> , 2006, 45, 216-217.	0.8	21
130	Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1631-1636.	0.6	30
131	Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. <i>Oncologist</i> , 2006, 11, 318-324.	1.9	116
132	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. <i>European Radiology</i> , 2005, 15, 1224-1233.	2.3	34
133	TGFÎ± expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005, 24, 3002-3010.	2.6	113
134	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. <i>Cancer</i> , 2005, 103, 1314-1315.	2.0	5
135	Target achieved. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1047-1048.	0.9	0
136	Continuation of Trastuzumab Beyond Disease Progression. <i>Journal of Clinical Oncology</i> , 2005, 23, 2866-2868.	0.8	20
137	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 1261-1267.	2.9	27
138	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072.	0.9	5
139	Incorporating Trastuzumab into the Neoadjuvant Treatment of HER2-Overexpressing Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 77-80.	1.1	21
140	HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. <i>Oncology Reports</i> , 2005, 13, 305-9.	1.2	18
141	A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer. <i>Oncology</i> , 2004, 66, 38-45.	0.9	48
142	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 81-96.	0.9	43
143	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 67-76.	1.1	225
144	HER2 and Central Nervous System Metastasis in Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 232-234.	1.1	10

#	ARTICLE	IF	CITATIONS
145	Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 185-190.	1.1	9
146	Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 330-340.	2.0	7
147	Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 95-97.	0.6	28
148	Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. <i>Radiologia Medica</i> , 2003, 106, 51-8.	4.7	13
149	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. <i>Clinical Breast Cancer</i> , 2000, 1, 197-209.	1.1	7
150	Immunophenotypic heterogeneity of hyalinizing trabecular tumours of the thyroid. <i>Histopathology</i> , 1997, 31, 525-533.	1.6	47